Boston biotech’s drug for rare liver disease will cost $385,000 a year

The day after winning its first US drug approval, Boston biotech Albireo Pharma on Wednesday disclosed that its new medicine for an ultrarare liver disease will come with an eye-popping average list price of $385,000 a year. Ron Cooper, the chief executive and president of Albireo, said Bylvay is the first medicine approved to treat progressive familial intrahepatic cholestasis, or PFIC, a deadly genetic disease that often leads to cirrhosis and liver failure in the first 10 years of life.

Read the source article at The Boston Globe
2021-07-21 04:00:00